莫西沙星对从人类腹腔内感染分离出的923株厌氧菌的体外活性。
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
作者信息
Goldstein Ellie J C, Citron Diane M, Warren Yumi A, Tyrrell Kerin L, Merriam C Vreni, Fernandez Helen
机构信息
R. M. Alden Research Laboratory, 2021 Santa Monica Blvd., Suite #740 East, Santa Monica, California 90404, USA.
出版信息
Antimicrob Agents Chemother. 2006 Jan;50(1):148-55. doi: 10.1128/AAC.50.1.148-155.2006.
Abstract
The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at < or = 1 microg/ml and 87% (79 of 90) B. thetaiotaomicron strains at < or = 2 microg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to < or = 2 microg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at < or = 2 microg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.
摘要
采用CLSI M11-A-6琼脂稀释法，研究了莫西沙星对923株近期从复杂性腹腔内感染患者预处理培养物中分离出的厌氧菌的体外活性。莫西沙星对87%（110株中的96株）的脆弱拟杆菌菌株在浓度≤1微克/毫升时具有活性，对87%（90株中的79株）的多形拟杆菌菌株在浓度≤2微克/毫升时具有活性。观察到种间差异，其中解脲拟杆菌、普通拟杆菌、梭状芽孢梭菌和共生梭菌最不敏感，且大多数耐药菌株均为此类；排除上述四种耐药菌，86%（363株拟杆菌属菌株中的303株）和94%（450株其他属和种中的417株）对浓度≤2微克/毫升的莫西沙星敏感。总体而言，莫西沙星对923株中的763株（83%）菌株在浓度≤2微克/毫升时具有活性，这支持了其作为某些社区获得性腹腔内感染单一疗法的应用。
相似文献
1
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.莫西沙星对从人类腹腔内感染分离出的923株厌氧菌的体外活性。
Antimicrob Agents Chemother. 2006 Jan;50(1):148-55. doi: 10.1128/AAC.50.1.148-155.2006.
2
Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.在希腊，拟杆菌属和普雷沃菌属菌种中普遍存在莫西沙星耐药性。
J Antimicrob Chemother. 2008 Jul;62(1):137-41. doi: 10.1093/jac/dkn134. Epub 2008 Apr 1.
3
Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.分析复杂性腹腔内感染患者的临床疗效和体外药敏与临床结局的相关性，研究应用莫西沙星治疗的效果。
Clin Infect Dis. 2011 Dec;53(11):1074-80. doi: 10.1093/cid/cir664. Epub 2011 Oct 12.
4
In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections.11种抗生素对从儿童腹腔内感染分离出的74株厌氧菌的体外活性。
Anaerobe. 2006 Apr;12(2):63-6. doi: 10.1016/j.anaerobe.2005.11.004. Epub 2005 Dec 27.
5
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.莫西沙星和左氧氟沙星对需氧及厌氧性腹腔内病原体的血清杀菌活性。
Anaerobe. 2008 Feb;14(1):8-12. doi: 10.1016/j.anaerobe.2007.09.005. Epub 2007 Oct 7.
6
Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).1997年至2002年6年间脆弱拟杆菌属菌群中氟喹诺酮耐药模式的变化
Diagn Microbiol Infect Dis. 2005 Nov;53(3):221-3. doi: 10.1016/j.diagmicrobio.2005.06.012. Epub 2005 Oct 21.
7
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.新型喹诺酮类药物莫西沙星对小鼠脆弱拟杆菌所致实验性腹腔脓肿的治疗效果
Chemotherapy. 2004 Jun;50(2):76-80. doi: 10.1159/000077806.
8
[Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].非腹泻性人类粪便中的脆弱拟杆菌群及其抗菌药敏性
Rev Esp Quimioter. 2006 Dec;19(4):357-62.
9
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.莫西沙星与亚胺培南/西司他丁治疗对不同脆弱拟杆菌和大肠埃希菌菌株静脉感染小鼠死亡率的影响。
J Antimicrob Chemother. 2004 Feb;53(2):318-24. doi: 10.1093/jac/dkh089. Epub 2004 Jan 16.
10
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.对包括厄他培南在内的七种抗菌药物针对希腊近期分离出的革兰氏阴性厌氧菌的体外活性进行的多中心调查。
Clin Microbiol Infect. 2005 Oct;11(10):820-4. doi: 10.1111/j.1469-0691.2005.01233.x.
引用本文的文献
1
Dialister pneumosintes and aortic graft infection - a case report.肺明串珠菌和主动脉移植物感染 - 病例报告。
BMC Infect Dis. 2023 Sep 19;23(1):617. doi: 10.1186/s12879-023-08584-3.
2
Alleviation of Hyperuricemia by Strictinin in AML12 Mouse Hepatocytes Treated with Xanthine and in Mice Treated with Potassium Oxonate.在黄嘌呤处理的AML12小鼠肝细胞及氧嗪酸钾处理的小鼠中，柯里拉京对高尿酸血症的缓解作用
Biology (Basel). 2023 Feb 17;12(2):329. doi: 10.3390/biology12020329.
3
CT findings and features of postoperative abdominal infection patients with pancreatic carcinoma.胰腺癌术后腹部感染患者的CT表现及特征
Pak J Med Sci. 2017 May-Jun;33(3):695-698. doi: 10.12669/pjms.333.12355.
4
Antianaerobic antimicrobials: spectrum and susceptibility testing.抗厌氧微生物药物：谱和药敏试验。
Clin Microbiol Rev. 2013 Jul;26(3):526-46. doi: 10.1128/CMR.00086-12.
5
2013 WSES guidelines for management of intra-abdominal infections.2013 WSES 腹腔内感染管理指南。
World J Emerg Surg. 2013 Jan 8;8(1):3. doi: 10.1186/1749-7922-8-3.
6
Global fluoroquinolone resistance epidemiology and implictions for clinical use.全球氟喹诺酮类药物耐药性流行病学及其临床应用意义
Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14.
7
Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing.基于 16S rRNA 基因深度测序，探究粪便微生物群移植相关多样性变化。
mBio. 2012 Oct 23;3(5):e00338-12. doi: 10.1128/mBio.00338-12.
8
Canadian practice guidelines for surgical intra-abdominal infections.加拿大外科腹腔内感染诊疗指南
Can J Infect Dis Med Microbiol. 2010 Spring;21(1):11-37. doi: 10.1155/2010/580340.
9
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.WSES 共识会议：腹腔内感染一线治疗管理指南。
World J Emerg Surg. 2011 Jan 13;6:2. doi: 10.1186/1749-7922-6-2.
10
Anaerobic infections: update on treatment considerations.厌氧感染：治疗注意事项的最新进展。
Drugs. 2010 May 7;70(7):841-58. doi: 10.2165/11534490-000000000-00000.
本文引用的文献
1
Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.厌氧细菌中抗生素耐药性的流行情况：令人担忧的发展态势。
Clin Infect Dis. 2004 Jul 1;39(1):92-7. doi: 10.1086/421558. Epub 2004 Jun 3.
2
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.腹腔内感染：细菌学、抗菌药物敏感性综述以及厄他培南在其治疗中的作用
J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii29-36. doi: 10.1093/jac/dkh201.
3
Moxifloxacin penetration into human gastrointestinal tissues.莫西沙星在人体胃肠道组织中的渗透情况。
J Antimicrob Chemother. 2004 May;53(5):875-7. doi: 10.1093/jac/dkh173. Epub 2004 Mar 31.
4
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.莫西沙星对900株来自腹腔内感染和糖尿病足感染患者的需氧及厌氧手术分离菌株的体外活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6. doi: 10.1128/AAC.48.3.1012-1016.2004.
5
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.莫西沙星与亚胺培南/西司他丁治疗对不同脆弱拟杆菌和大肠埃希菌菌株静脉感染小鼠死亡率的影响。
J Antimicrob Chemother. 2004 Feb;53(2):318-24. doi: 10.1093/jac/dkh089. Epub 2004 Jan 16.
6
Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.复杂性腹腔内感染抗微生物药物选择指南。
Clin Infect Dis. 2003 Oct 15;37(8):997-1005. doi: 10.1086/378702. Epub 2003 Sep 25.
7
Emergence of fluoroquinolone resistance among Bacteroides species.拟杆菌属中氟喹诺酮耐药性的出现。
J Antimicrob Chemother. 2003 Aug;52(2):208-13. doi: 10.1093/jac/dkg320. Epub 2003 Jul 15.
8
Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.脆弱拟杆菌群所致菌血症：菌种分布、β-内酰胺酶产生情况及抗菌药物敏感性模式
Antimicrob Agents Chemother. 2003 Jan;47(1):148-53. doi: 10.1128/AAC.47.1.148-153.2003.
9
In vitro activities of newer quinolones against bacteroides group organisms.新型喹诺酮类药物对拟杆菌属微生物的体外活性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. doi: 10.1128/AAC.46.10.3276-3279.2002.
10
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.脆弱拟杆菌群对新型喹诺酮类药物及其他标准抗厌氧菌药物的敏感性。
J Antimicrob Chemother. 2001 Jul;48(1):127-30. doi: 10.1093/jac/48.1.127.
Zotero 插件